Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer

Diagnostic Cytopathology

Volumn 34, Issue 11, 2006, Pages 739-748

  Branca, M ^a   Giorgi, C ^a   Ciotti, M ^b   Santini, D ^c   Di Bonito, L ^d   Costa, S ^c   Benedetto, A ^b   Bonifacio, D ^d   Di Bonito, P ^a   Paba, P ^b   Accardi, L ^a   Mariani, L ^e,e   Ruutu, M ^f   Syrjanen S ^f   Favalli, C ^b   Syrjänen, Kari ^a,g   Leoncini, L ^a   Alderisio, M ^a   De Nuzzo, M ^c   Zanconati, F ^d   Sesti, F ^h   Criscuolo, A ^h   Piccione, E ^h   Galati, M ^e,i   Agarossi, A ^j   Casolati, E A ^j   Valieri, M ^j   Di Carlo, A ⁱ   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF TURKU   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Cervical cancer; hTERT; Oncogenic human papillomavirus; Persistence; Prognosis; Telomerase; Treatment; Virus clearance

Indexed keywords

PRIMER DNA; PROTEIN E6; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CELL IMMORTALIZATION; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME ASSAY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TELOMERE; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS PATHOGENESIS; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 33750520746     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20554     Document Type: Article

References (62)

1. Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. Chichester: Wiley; 2000. p 1-615.
2. Aubin F, Pretet JL, Mougin C, editors. Papillomavirus humains, Biologie et pathologie tumorale. Paris: Editions TEC & DOC: 2003. p 1-759.
3. Campo S, editor. Papillomavirus research: From natural history to vaccines and beyond. Norwich, UK: Caister Academic; 2006. p 1-424.
4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
5. Cliffort GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: Pooled analysis. Lancet 2005;366:991-998.
6. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-2242.
7. Longatto Filho A, Utagawa ML, Shirata NK, et al. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 2005;24:118-124.
8. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;:78:11451-11460.
9. INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-365.
10. Branca M, Ciotti M, Santini D, et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004;122:902-911.
11. Fehrman F, Laiminis LA. Human papillomaviruses: Targeting differentiated epithelial cells for malignant transformation. Oncogene 2003;22:5201-5207.
12. Creider CW. Telomere length regulation. Annu Rev Biochem 1996;65:337-365.
13. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
14. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995;269:1236-1241.
15. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82.
16. Stoppler H, Hartmann DP, Sherman L, Schlegel R. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length. J Biol Chem 1997;272:13332-13337.
17. Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 2001;75:4467-4472.
18. Gewin L, Galloway DA. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol 2001;75:7198-7201.
19. Sagawa Y, Nishi H, Isaka K, Fujito A, Takayama M. The correlation of TERT expression with c-myc expression in cervical cancer. Cancer Lett 2001;168:45-50.
20. Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: Induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol 2001;75:5559-5566.
21. Veldman T, Liu X, Yuan H, Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci USA 2003;100:8211-8216.
22. McMurray HR, McCance DJ. Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7. J Virol 2004;78:5698-5706.
23. Gewin L, Myers H, Kiyono T, Galloway DA. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004;18:2269-2282.
24. Jeong Seo E, Jung Kim H, Jae Lee C, Tae KH, Seong HE. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells. Gynecol Oncol 2004;94:40-47.
25. Peitsaro P, Ruutu M, Syrjanen S, Johansson B. Divergent expression changes of telomerase and E6/E7 mRNA, following integration of human papillomavirus type 33 in cultured epithelial cells. Scand J Infect Dis 2004;36:302-304.
26. Anderson S, Shera K, Ihle J, et al. Telomerase activation in cervical cancer. Am J Pathol 1997;151:25-31.
27. Pao CC, Tseng CJ, Lin CY, et al. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J Clin Oncol 1997;15:1932-1937.
28. Gorham H, Yoshida K, Sugino T, et al. Telomerase activity in human gynaecological malignancies. J Clin Pathol 1997;50:501-504.
29. Iwasaka T, Zheng PS, Yokoyama M, Fukuda K, Nakao Y, Sugimori H. Telomerase activation in cervical neoplasia. Obstet Gynecol 1998;91:260-262.
30. Zhang DK, Ngan HY, Cheng RY, Cheung AN, Liu SS, Tsao SW. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur J Cancer 1999;35:154-160.
31. Stanta G, Bonin S, Niccolini B, Raccanelli A, Baralle F. Catalytic subunit of telomerase expression is related to RNA component expression. FEBS Lett 1999;460:285-288.
32. Wang SJ, Sakamoto T, Yasuda Si S, et al. The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 2002;84:81-84.
33. Jarboe EA, Liaw KL, Thompson LC, et al. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene 2002;21:664-673.
34. Frost M, Bobak JB, Gianani R, et al. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am J Clin Pathol 2000;114:726-734.
35. Zhang A, Zheng C, Hou M, et al. Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer 2002;34:269-275.
36. Branca M, Giorgi C, Santini D, et al. Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006;59:40-47.
37. Syrjanen KJ. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:118-124.
38. Branca M, Costa S, Mariani L, et al. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 2004;25:689-98.
39. Costa S, Terzano P, Santini D, et al. CD44 isoform 6 (CD44v6) is a prognostic indicators of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2001;80:67-73.
40. Costa S, Terzano P, Santini D, et al. Neoadjuvant chemotherapy in cervical carcinoma: Regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 2001;116:729-737.
41. Costa S, Simone PD, Venturoli S, et al. Factors predicting human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 2003;90:358-365.
42. Hiyama E, Hiyama K, Yokoyama T, Shay JW. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 2001;3:17-26.
43. Bauer HM, CE Greer CE, Manos M. Determination of genital human papillomavirus infection using consensus PCR. In: Herrington CS, McGee JOD, editors. Diagnostic molecular pathology: A practical approach. Oxford: Oxford University Press; 1992. p 132-152.
44. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-2100.
45. Kleter B, van Doorn LJ, Scrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-2517.
46. Branca M, Giorgi C, Santini D, et al. Aberrant expression of a novel inhibitor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-121.
47. Branca M, Giorgi C, Ciotti M, et al. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J Clin Pathol, in press.
48. Kyo S, Takakura M, Tanaka M, Kanaya T, Inoue M. Telomerase activity in cervical cancer is quantitatively distinct from that in its precursor lesions. Int J Cancer 1998;79:66-70.
49. Wisman GB, de Jong S, Meersma GJ, et al. Telomerase in (pre)neoplastic cervical disease. Hum Pathol 2000;31:1304-1312.
50. Herbsleb M, Knudsen UB, Orntoft TF, et al. Telomerase activity, MIB-1. PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. APMIS 2001;109:607-617.
51. Zhang A, Wang J, Zheng B, et al. Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix. Oncogene 2004;23:7441-7447.
52. Wisman GB, Hollema H, de Jong S, et al. Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol 1998;16:2238-3345.
53. Reddy VG, Khanna N, Jain SK, Das BC, Singh N. Telomerase-A molecular marker for cervical cancer screening. Int J Gynecol Cancer 2001;11:100-106.
54. Reesink-Peters N, Helder MN, Wisman GB, et al. Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol 2003;56:31-35.
55. Jarboe EA, Thompson LC, Heinz D, McGregor JA, Shroyer KR. Telomerase and human papillomavirus as diagnostic adjuncts for cervical dysplasia and carcinoma. Hum Pathol 2004;35:396-402.
56. Tsezou A, Oikonomou P, Kollia P, Mademtzis I, Kostopoulou E, Messinis I, et al. The role of telomerase catalytic subunit mRNA expression in cvical dysplasia. Exp Biol Med 2005;230:263-270.
57. Wisman GB, Knol AJ, Helder MN, et al. Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer, Int J Cancer 2001;91:658-664.
58. Kyo S, Takakura M, Ishikawa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res 1997;57:1863-1867.
59. Kawai K, Yaginuma Y, Tsuruoka H, Griffin M, Hayashi H, Ishikawa M. Telomerase activity and human papillomavirus (HPV) infection in human uterine cervical cancers and cervical smears. Eur J Cancer 1998;34:2082-2086.
60. Zheng PS, Iwasaka T, Zhang ZM, Pater A, Sugimori H. Telomerase activity in Papanicolaou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papillomaviruses. Gynecol Oncol 2000;77:394-398.
61. Saretzki G, Fischer H, Kaufmann IG, Schewe C, Nadjari B, Blohmer J, et al. Telomerase activity in cervical smears. Anal Cell Pathol 2001;23:39-43.
62. Cheung AN, Chiu PM, Tsun KL, Khoo US, Leung BS, Ngan HY. Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. J Clin Palhol 2004;57:721-727.